Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy August 30, 2021
Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta Variant August 25, 2021
Anixa Biosciences Congratulates Director, Dr. Arnold Baskies for His Appointment to the WHO's Global Breast Cancer Initiative August 23, 2021
Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology August 18, 2021
Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic May 26, 2021
Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND Application May 20, 2021
Anixa Biosciences and Moffitt Cancer Center Report US FDA Request of Additional Information for CAR-T Therapy April 19, 2021
Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic April 5, 2021
Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million March 22, 2021